Guggenheim maintained a Buy rating on Merck (NYSE:MRK) shares but reduced the price target to $115 from $122. The adjustment follows a comprehensive review of the pharmaceutical giant's fourth-quarter ...
The waveLINE-010 trial will compare zilovertamab vedotin, in combination with rituximab plus cyclophosphamide, doxorubicin, ...
Co., Inc. (NYSE: MRK) has initiated a pivotal Phase 3 clinical trial, waveLINE-010, to evaluate the efficacy of its investigational drug zilovertamab vedotin in treating patients with previously ...
Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...
Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, ...
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the initiation of waveLINE-010, a pivotal ...
The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.
Dr Marjorie Green, head of global clinical development, oncology, at Merck Research Labs, said the subcutaneous route "has the potential to improve the patient experience as well as increase ...
The late research pioneer Roberta (“Bobbie”) Colman, Willis F. Harrington Professor of Chemistry and Biochemistry at UD, had ...
"Daily single-tablet regimens have helped to transform HIV care but can be challenging for some people to maintain," said Dr Elizabeth Rhee, head of Merck Research Laboratories. "Novel HIV ...
The more complex and labor-intensive esoteric tests are reimbursed at a higher rate and often outsourced by hospitals to independent labs. Labcorp is funneling resources to broaden its menu of complex ...
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback